Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Methemoglobin formation refers to the oxidative process by which hemoglobin is converted into methemoglobin, where the iron within the heme group is oxidized from its normal ferrous (Fe²⁺) state to a ferric (Fe³⁺) state. This oxidation renders methemoglobin incapable of binding and transporting oxygen. Elevated levels impair oxygen delivery to tissues, leading to methemoglobinemia, characterized by cyanosis and hypoxia. Red blood cells possess enzyme systems to reduce methemoglobin back to functional hemoglobin, primarily via NADH-dependent cytochrome b₅-methemoglobin reductase. Deficiencies in these enzymes can result in persistent methemoglobinemia. Treatment may involve methylene blue to accelerate reduction back to functional hemoglobin.
Methylene blue accelerates the reduction of methemoglobin to hemoglobin via alternative enzymatic pathways.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Methemoglobin Formation.